NJ Court Not Sure Bristol-Myers Investor Pled Negligence
A New Jersey appellate panel on Tuesday pushed back on an investor's insistence that his complaint over Bristol-Myers Squibb's $74 billion acquisition of Celgene satisfied pleading standards for securities lawsuits, echoing...To view the full article, register now.
Already a subscriber? Click here to view full article